Amarin (AMRN)
(Delayed Data from NSDQ)
$0.88 USD
0.00 (0.24%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $0.88 0.00 (0.34%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.88 USD
0.00 (0.24%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $0.88 0.00 (0.34%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth C Momentum C VGM
Zacks News
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks
by Zacks Equity Research
Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa.
Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars
by Zacks Equity Research
Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors in Amarin (AMRN) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Moving Average Crossover Alert: Amarin (AMRN)
by Zacks Equity Research
Amarin Corporation plc (AMRN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Surging implied volatility makes Amarin (AMRN) stock lucrative to the option traders.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Surging implied volatility makes Amarin (AMRN) Stock lucrative to the option traders.
Amarin (AMRN) Soars: Stock Adds 9.9% in Session
by Zacks Equity Research
Amarin Corporation (AMRN) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors in Amarin Corporation plc (AMRN) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors in Amarin Corporation plc (AMRN) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Amarin Corporation (AMRN) Stock?
by Zacks Equity Research
Investors in Amarin Corporation plc (AMRN) need to pay close attention to the stock based on moves in the options market lately.
Ocera Therapeutics (OCRX) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Ocera Therapeutics (OCRX) saw its shares rise almost 7% in the last trading session.
Zacks.com featured highlights: Amarin, Two Harbors Investment, Fairmount Santrol Holdings, Vale and Oclaro
by Zacks Equity Research
Zacks.com featured highlights: Amarin, Two Harbors Investment, Fairmount Santrol Holdings, Vale and Oclaro
New Strong Buy Stocks for October 18th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include AMRN, CGEN, RPTP, MT and HOV.